In the era of next-generation sequencing, knowledge of the genomic drivers of breast cancer and resistance to treatment is expanding. The recognition that these molecular drivers are ubiquitous in alldoi:10.1007/978-3-319-60336-0_12Ana Christina Garrido-Castro...
Approximately 235,000 new cases of invasivebreast cancerare diagnosed each year. Of these, approximately half of patients who develop metastatic disease will have cancer spread (metastasize) to the liver, explained Lewandowski. While chemotherapy is the standard treatment for these women, many will ei...
(ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer and who have not yet received an endocrine-based therapy. Continued approval for this indication may be contingent on positive results from a confirmatory phase 3 trial, PALOMA-2, which is now ...
“New treatments for metastatic breast cancer are needed, as many patients become resistant to existing therapies,” said Captain Melissa Kaime, M.D., Director of the Congressionally Directed Medical Research Programs (CDMRP), under which the BCRP is managed. “The novel studies presented at...
Smith G, Henderson C: New treatments for breast cancer. Semin Oncol 23:506-528, 1996Smith G, Henderson IC: New treatments for breast cancer. Semin Oncol 23(4): 506 28, 1996.Smith G, Henderson IC. New treatments for breast cancer. Semin Oncol 23:506-528, 1996....
New treatments for metastatic breast cancer: Mechanisms of action of nanoparticle albumin-bound taxanes The combination of physiologically interactive albumin with pharmaceutical agents in the nanoparticle state has emerged as an important new strategy for chemotherapy. This strategy exploits the natural prope...
" and perhaps most importantly by the consolidation of a new clinical category, HER2-low, which represents a more nuanced picture in the treatment of metastatic breast cancer. In the revised scheme, a subgroup of patients previously considered as HER2-negative are now redefined as an autonomous ...
Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.In an interview with Pharmacy Times, Kelly Gaertner, PharmD, an oncology clinical pharmacy specialist with Allegheny Health Network, said that a slew of new treat...
Despite the increased efficacy and survival offered by agents such as the taxanes, drug resistance remains a significant barrier to further reductions in mortality rates for patients with metastatic breast cancer (MBC). Epothilones, a new class of microtubule-stabilizing drugs that are structurally dis...
The cancer is known as “advanced hormone receptor positive, HER 2 negative” breast cancer. Women with these tumors are often given drugs called aromatase inhibitors, which work by reducing estrogen in the body and slowing the growth of the cancer. ...